PANCREATIC ADENOCARCINOMA

This study tests a wearable device that creates electric fields (TTFields) combined with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that can be surgically removed. Participants receive the treatment for three cycles before surgery an…

This study tests whether adding two targeted drugs (defactinib and avutometinib) to a precise form of radiation therapy can help people with advanced pancreatic cancer live longer without their disease getting worse. About 36 adults whose cancer is locally advanced or borderline …

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors that have not responded to standard treatments. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 230 adults with certain cancers like lung, …

This early-stage study tests a new drug called PF-08046876 in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. The drug is designed to stick to cancer cells and kill them directly. The main goals are to check safety, find the best dose, an…

This early-phase study tests a new drug, CLSP-1025, in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have a specific genetic change called p53 R175H and a certain immune type (HLA-A*02:01). The goal is to find a safe dose and see if the drug can …

This study tests a tiny radiation device placed directly into pancreatic tumors, combined with standard chemotherapy. It aims to see if the treatment is safe and helps control pain. About 40 people with advanced or spread pancreatic cancer will take part.

This early-stage trial tests the safety of adding the targeted drug sotorasib to standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12C. About 15 participants will receive the combination as their first treatment. The …

This early-stage trial tests an experimental drug, MRTX1719, in adults with advanced solid tumors that have a specific genetic change (loss of the MTAP gene). The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants wit…

This study tests a new approach for advanced pancreatic cancer that cannot be removed by surgery. Doctors place tiny devices called Alpha DaRT seeds directly into the tumor to deliver a special type of radiation from the inside. The main goals are to see if the procedure is safe …

This study tests a new drug, BMS-986340, alone or with other cancer treatments in people with advanced solid tumors that have not responded to standard therapy. The main goal is to find safe doses and check for side effects. About 949 adults with various cancers like lung, breast…

This study tests whether adding the experimental drug atebimetinib to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will be randomly assigned to receive either the new combination or standard ch…

This early-stage study tests a new drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 574 people with lung, colorectal, or panc…

This early-stage trial tests whether adding Tumor Treatment Fields (TTF) – a device that sends low-intensity electric fields to the tumor – to a three-drug chemotherapy regimen can help control metastatic pancreatic cancer. About 40 adults whose cancer has spread to the liver wil…

This study tests whether the immunotherapy drug dostarlimab works better than standard chemotherapy as the first treatment for people with advanced cancers that have specific genetic markers (dMMR/MSI). The cancers studied are rare types like pancreatic, stomach, and small bowel …

This study tests an experimental drug called ESK981 in people with advanced pancreatic cancer, certain neuroendocrine tumors, or neuroendocrine prostate cancer. Participants take ESK981 capsules in a 5-days-on, 2-days-off cycle. The main goal is to see if the drug can keep the ca…

This early-phase study tests whether adding two new drugs (elraglusib and retifanlimab) to standard chemotherapy can help people with advanced pancreatic cancer that hasn't been treated before. The main goal is to check safety and find the right dose. Up to 12 adults will take pa…

This study tests a new way to treat advanced pancreatic cancer by combining a drug called Nivolumab (which helps the immune system fight cancer) with a procedure called irreversible electroporation (which uses electric pulses to destroy tumor cells). The goal is to see if this co…

This early-phase study tests a new drug, ASP2138, that helps the immune system find and attack cancer cells that have a specific marker called CLDN18.2. The study includes adults with advanced stomach, gastroesophageal junction, or pancreatic cancer that cannot be removed by surg…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This study tests whether adding the anti-inflammatory drug anakinra to standard chemotherapy can help people with pancreatic cancer that can be removed by surgery. About 24 adults with early-stage or locally advanced pancreatic cancer will receive the drug combination before and …

This study tests a new drug called daraxonrasib, either alone or with standard chemotherapy, for people with metastatic pancreatic cancer that has spread. About 900 adults with a RAS gene mutation will be randomly assigned to one of three treatment groups. The goal is to see if t…

This early-phase study tests a new combination of five chemotherapy drugs for people with advanced cancers of the upper digestive system, including pancreatic and stomach cancers. The goal is to find the safest dose based on a person's genetic makeup, which affects how the body p…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or other solid tumors that have a specific marker (CLDN18.2). The trial has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, and Part 2 tests th…

This study tests a major surgery combined with heated chemotherapy (HIPEC) for people with pancreatic cancer that has spread to the abdomen. Participants first receive standard chemo for at least 6 months, then undergo surgery to remove the tumor and visible cancer spots, followe…

This study tests a new drug called APL-5125 in about 100 adults with advanced solid tumors, including colorectal, pancreatic, and ovarian cancers. The goal is to check safety and see if the drug can shrink tumors. Participants must have tried standard treatments first.

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific genetic mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses a patient's own immune cells, which are …

This study tests if adding a low-dose EGFR blocker (erlotinib) to standard chemotherapy works better for people with a specific type of advanced pancreatic cancer called 'basal-like.' Participants first get a test to classify their tumor. Those with basal-like cancer may receive …

This study is testing a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. Doctors place tiny devices that release a special type of radiation directly into the tumor. The goal is to see if this is safe and possible to do, and to check if i…

This early-stage trial is testing the safety of a new two-part treatment for people with advanced HER2-positive solid tumors, such as breast, lung, or gastric cancer. First, a specially designed virus is injected directly into one tumor to help alert the immune system. A few days…

This study tests a dye that makes pancreatic cancer cells glow during surgery, helping surgeons see and remove them more completely. About 27 people with pancreatic cancer who are already scheduled for surgery will receive the dye beforehand. The goal is to see if the dye is safe…

This study is testing whether a new type of PET scan (68Ga-FAPI-46) can better detect the spread of pancreatic and bile duct cancers compared to standard CT and MRI scans. About 120 adults with newly diagnosed, potentially curable cancer will receive the new scan. If it proves mo…

This study is testing a new blood test that looks for tiny particles called exosomes to find pancreatic cancer early. Researchers will study 2,000 people, including those with and without the disease, to see how accurate the test is. If successful, it could lead to earlier diagno…

This study looks at whether a program of exercise and nutrition during chemotherapy can help elderly patients (65+) with ovarian or pancreatic cancer get stronger before surgery. About 22 participants will follow the program to see if they can stick with it. The goal is to improv…

This study collects medical information, blood, tissue, and other samples from up to 20,000 people with pancreas diseases like pancreatic cancer or pancreatitis. The goal is to build a resource that helps researchers better understand these conditions and develop better screening…

This study looks at whether using a fitness tracker (like a Fitbit) can give doctors a better picture of how advanced cancer patients are functioning day-to-day. About 590 people with various cancers will wear activity monitors. The goal is to see if the activity data matches up …